What is Vaxneuvance, injection suspension used for?

( ARTG ) VAXNEUVANCE is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F) in adults and children from 6 weeks of age. VAXNEUVANCE may not prevent disease caused by S. pneumoniae serotypes that are not contained in the vaccine. The use of VAXNEUVANCE should be guided by official recommendations.

What are the side effects of Vaxneuvance, injection suspension?

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme

Who manufactures Vaxneuvance, injection suspension?

MSD Merck Sharp & Dohme AG (CH)

What ATC class does Vaxneuvance, injection suspension belong to?

Vaxneuvance, injection suspension: ATC J07AL02. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

OTC

Vaxneuvance, injection suspension

Data updated: 2026-04-11

Available in:

🇨🇿🇩🇪🇬🇧🇸🇰

Form

—

Dosage

—

Route

—

Storage

—

About This Product

Manufacturer

MSD Merck Sharp & Dohme AG

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.